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Transcription factors (TFs), the key players in transcriptional regulation, have attracted great 
experimental attention, yet the functions of most human TFs remain poorly understood. Recent 
capabilities in genome-wide protein binding profiling have stimulated systematic studies of the 
hierarchical organization of human gene regulatory network and DNA-binding specificity of TFs, 
shedding light on combinatorial gene regulation. We show here that these data also enable a 
systematic annotation of the biological functions and functional diversity of TFs. We compiled a 
human gene regulatory network for 384 TFs covering the 146,096 TF-target gene relationships, 
extracted from over 850 ChIP-seq experiments as well as the literature. By integrating this 
network of TF-TF and TF-target gene relationships with 3,715 functional concepts from six 
sources of gene function annotations, we obtained over 9,000 confident functional annotations for 
279 TFs. We observe extensive connectivity between transcription factors and Mendelian 
diseases, GWAS phenotypes, and pharmacogenetic pathways. Further, we show that transcription 
factors link apparently unrelated functions, even when the two functions do not share common 
genes. Finally, we analyze the pleiotropic functions of TFs and suggest that increased number of 
upstream regulators contributes to the functional pleiotropy of TFs. Our computational approach 
is complementary to focused experimental studies on TF functions, and the resulting knowledge 




Regulation of gene expression is essential for the realization of cell type specific phenotypes 
(Whyte et al. 2013) during normal development (Reik 2007) and the adaptation of cellular 
organisms to their environment (López-Maury et al. 2008). To a large degree, transcriptional 
regulation occurs through the interaction of protein factors with the genomic DNA (Lenhard et al. 
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2012). Multiple proteins, including the chromatin remodelers, transcription factors, cofactors and 
other transcription initiation factors (Perissi and Rosenfeld 2005) work in coordination to regulate 
the spatial-temporal details of gene expression. Transcription factors (TFs) bind DNA in a 
sequence specific manner and mediate the integrations of other proteins with specific target genes 
for fine-granular expression control (Maniatis et al. 1987).  
 
The pivotal role of TFs in development and cell identity determination is highlighted by the 
induced pluripotent stem cell (iPSC) technology (Takahashi and Yamanaka 2006; Park et al. 2008) 
and trans-induction techniques (Lee and Young 2013; Jopling et al. 2011), in which the 
introduction of just a few specific transcription factors is sufficient for converting fibroblast cell 
into pluripotent stem cell, or converting one differentiated cell type, e.g. pancreatic exocrine cell, 
directly into another differentiated cell type, e.g. β-cell. In addition, transcription factors are key 
players controlling diverse physiological functions ranging from metabolism (Yamashita et al. 
2001; Wang et al. 2011), chemical and  mechanical stress responses (Kaspar et al. 2009; Tothova 
et al. 2007; Kumar and Boriek 2003; Mendez and Janmey 2012), song-learning (Whitney et al. 
2014; Pfenning et al. 2012), to longevity and aging (Greer and Brunet 2005; Salih and Brunet 
2008; Tilstra et al. 2012). Many TFs are directly involved in diseases, such as cancer, diabetes, 
and neural developmental disorders (Lee and Young 2013).  
 
Transcription factors have attracted intense research attention (Yusuf et al. 2012); yet the 
biological functions of most TFs are still poorly understood. The number of human TFs is 
estimated to be around 1500-2000 based on DNA-binding domain evidence (Vaquerizas et al. 
2009; Ravasi et al. 2010; Ashburner et al. 2000; Kummerfeld and Teichmann 2006). In total, the 
sequence-specific DNA-binding activities of only 564 TFs are confirmed by experimental 
evidence and the existence of an additional 490 is supported indirectly by phylogenetic evidence 
or author claims (The Gene Ontology Consortium 2015). Limited knowledge is available on the 
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biological functions of most TFs, with a small number of “famous” TFs such as TP53 attracting 
much attention (Vaquerizas et al. 2009). However, recent development of high-throughput 
technology such as ChIP-seq and DNase-seq (Furey 2012) provide an unprecedented amount of 
data on gene regulation, with binding profiles for over 100 transcription factors from ENCODE 
alone (Gerstein et al. 2012). This has spurred systematic data-driven studies on transcriptional 
regulation, such as the discovery of cis-regulatory motifs (Kheradpour and Kellis 2014; Jolma et 
al. 2013), the mapping of the hierarchical architecture of human gene regulatory network, and the 
modeling of combinatorial regulation (Gerstein et al. 2012; Cheng et al. 2011b; Neph et al. 2012; 
Bernstein et al. 2012; Jiang and Singh 2014). At the same time, analytics tools have been 
developed for annotating ChIP-seq data (Ji et al. 2011; Zhang et al. 2008; Spyrou et al. 2009), 
some allowing analysis of gene ontology term enrichment for the binding sites (Zhu et al. 2010; 
McLean et al. 2010; Welch et al. 2014). 
 
In this study, we integrate the existing knowledge about functions and phenotypes of human 
genes with the transcriptional regulatory network to study the functions of human transcription 
factors. We define the “target functions” of a TF as the statistical overrepresented functions 
among its target genes, and provide a systematic annotation of TF functions, ranging from 
metabolic pathways to disease phenotypes. In parallel, we define the functional similarity of two-
TFs based on their target gene overlaps, independent of the availability of gene function 
annotations, and annotate each TF by functionally similar TFs (Fig. 1). We study the pleiotropic 
functions of individual TFs and show that multifunctionality is associated with the number of 
upstream regulators of the TFs. With these analyses, we demonstrate a computational approach 




The Compendium of Human Transcription Factor Target Genes 
We compiled a Transcription Factor-Target Gene (TFTG) data compendium covering the direct 
transcriptional regulation targets of 384 unique transcription factors (TFs) extracted from over 
850 ChIP-seq experiments as well as the literature with low throughput experimental evidence. 
Low throughput experiments, ENCODE ChIP-seq, and other sources of ChIP-seq data are 
complementary in their TF coverage. 149 (39%) TFs are covered only by high-throughput 
experiments, among which 52 (35%) are covered by the ENCODE consortium (Gerstein et al. 
2012; Bernstein et al. 2012), 107 are covered by individual research labs (based on data published 
by October 2013). Meanwhile 122 (32%) TFs are only from low throughput experiments, and 113 
(29%) TFs are from both low and high throughput experiments (Fig. S1A). 
 
There are in total 16,967 unique target genes (TGs) of TFs, including both transcription factors 
and non-transcription factors. We filtered the target genes identified in high-throughput 
experiments to achieve an estimated false discovery rate of 0.01. Combining all sources, 146,096 
TF-TG relationships are obtained. Each gene is regulated by 8.6 TFs on average, while each TF 
regulates 380.5 genes (see Fig. S1B). 63% of target genes are each regulated by 5 or more TFs, 
while 18% are each regulated by a single TF. Most TFs also have regulators within the 
compendium, with the exception of 14 TFs that appear to be master regulators, including BCOR, 
GLI2, HLF, HNF4G, MAZ, NELFE, NFATC1, NOTCH1, PHOX2A, RXRA, STAT4, SOX10, 
TEAD2 and THRA, although RXRA and SOX10 are self-regulated.  
 
Defining the Target Functions of Transcription Factors 
Transcription factors perform their functions by i) interacting with proteins and cis-regulatory 
elements and ii) consequently regulating the expression of downstream target genes. There are 
hence two aspects of functions for a TF, the molecular functions of a TF that enables its 
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regulation of the target genes, and the biological functions exerted by the genes that are under 
control of the TF. Formally, we define the target functions (e.g. target diseases, target signaling 
pathways) of a transcription factor as the consensus functions of the target genes, and we identify 
the target functions of a TF by detecting the enrichment of functional terms in the target genes. 
The target genes as a whole precisely define the biological functions regulated by a TF, while the 
target functions summarize the functional impacts upon perturbation of a transcription factor. 
 
We first compiled 3715 functional concepts covering molecular to organism level functions 
(Table S1), including Mendelian diseases from OMIM, disease and phenotype associations from 
dbGAP genome wide association studies (GWAS), pharmacokinetic (PK) and pharmacodynamics 
(PD) pathways from PharmGKB, signaling and metabolic pathways from Reactome, and 
molecular functions and biological processes from Gene Ontology (GO). There are significant 
overlaps among the genes annotated in the six sources, yet each source has some unique genes 
(Fig. S2.)  
 
We then confirmed the presence of functional signals in the TFTG compendium, i.e., TFs are not 
randomly targeting functionally unrelated genes, and the TFTG compendium contains significant 
number of true target genes. We compared the TF-Function associations obtained using real 
TFTG compendium against that obtained using a randomized compendium, where we constructed 
the fake TFs to have the same number of random target genes as the corresponding real TFs. We 
observed 237,566 TF-Function pairs with p-values for real TFs smaller than the corresponding p-
values for the fake TFs, compared to 155,801 pairs showing the opposite relationship (Fig. 2). To 
estimate the total number of true associations present for the real TFs, we assume i) true 
associations for real TFs are all in the upper triangle, i.e. having p-values from real compendium 
less than corresponding p-values from randomized compendium; ii) false associations for real 
TFs equally distribute in the upper and lower triangle, i.e. having similar p-values from the real 
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and fake TFs. This leads to an estimated 81,765 true target function annotations for the real TFs. 
The ratio between the true and false associations is larger at the smaller p-value regions (Fig. 2 
inset). At p-value cutoff of 0.001, there are 16,158 associations for real TFs and 999 for fake TFs, 
corresponding to an FDR of 6.18%; while at p-value cutoff of 0.0001, there are 9,132 
associations for real TFs but only 130 for fake TFs, corresponding to an FDR of 1.42%.  
 
Gene Universe Impacts the Detection of Target Functions 
The target functions of a transcription factor are detected by identifying statistically significant 
enrichment of functional terms among the target genes of the TF. A critical step for obtaining 
proper statistics for enrichment analysis is the choice of gene universe, which is the “allowed” set 
of genes that restrict the target genes of a TF as well as the member genes of a functional term to 
be used in determining statistical associations. In Fig. S3, we show the example of TF SP1 and 
functional term “immune system”. The choice of gene universe affects not only the significance 
(p-value) but also the direction of TF-target function association. In general, an overly large gene 
universe inflates the strength of positive association, i.e. enrichment of functional terms, while an 
overly restrictive gene universe inflates the strength of negative association, i.e. depletion of 
functional terms.  
 
We suggest that the gene universe must be chosen based on the implicit limitations of each type 
of functional annotations stemming from how the annotation was obtained, thus generally 
providing a smaller and hence more conservative universe.  For manual curation, such as OMIM 
and PharmGKB, the function annotations are limited by the available literature. We hence 
constructed a conservative “Literature Rich” gene universe that includes protein-coding genes 
annotated by one or more sources from OMIM, PharmGKB, GO BP, GO MF, Reactome, KEGG, 
and Biocarta. For machine annotations coming from high throughput experiments followed by 
computational filtering, such as the GWAS phenotype annotations, we use the “Coding Genes” as 
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a conservative universe (see Methods for more details). We disregard non-coding genes as they 
are generally poorly annotated. We used the Literature Rich gene universe to detect target 
Mendelian diseases, pharmacogenomic pathways, signaling/metabolic pathways, molecular 
functions, and biological processes, and used the Coding gene universe to detect target 
phenotypes studied in GWAS.  
 
Transcription Factor-Target Function Network  
At false discovery rate of 0.05, we identified 9,747  significant TF-target function relationships 
using the conservative gene universes (Fig. 3A). The TF-target function associations form a 
scale-free network (Barabási 1999), with power law distributions for both the number of target 
functions per TF and the number of TFs per target function (Fig. 3B and Fig. S4A). Overall, 279 
(73%) transcription factors are annotated by at least one functional term (Supplemental Material 
Section 1.1). The lack of the annotations of the remaining TFs is likely due to small sample size, 
i.e. number of target genes. The un-annotated TFs have 26.3 target genes on average, compared to 
519.0 target genes on average for annotated TFs (Fig. S4B). An average TF is positively 
associated with 0.47 Mendelian diseases, 0.052 GWAS phenotypes or diseases, 0.26 
pharmacogenomic pathways, 11.2 signaling and metabolic pathways, 7.9 biological processes, 
and 1.4 molecular functions (Table S2). Extensive regulator sharing is observed among different 
types of gene functions (Fig. S5A), while we also observed biases of 62 TFs towards specific 
types of functions (Fig. S5B and Supplemental Material Section 1.2).  
 
Target Functions Predict Known Functions of Transcription Factors 
We globally validate the TF-target function relationships by comparing them against the known 
functions of these transcription factors. Of course, our TF-target function relationships do not 
necessarily map to a TF-function relationship that is covered by existing gene annotation 
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databases. For example, AHR targets molecular function “oxygen binding”, indicating that AHR 
regulates proteins that bind oxygen and likely catalyze oxidation reactions, but this does not mean 
oxygen binding is a molecular function of AHR protein itself. HNF1A targets many 
pharmacokinetic pathways (Fig. 3G), but HNF1A is naturally not an annotated member of these 
pharmacokinetic (PK) pathways, as the PK pathways in PharmGKB focus on the metabolic 
enzymes and transporters of drugs. Despite that, we find that the TF-target function associations 
can predict the known TF-target function relationships for all six types of functions. An overall 
area under the ROC curve (AUC) of 0.80 is achieved by using the p-value from Fisher’s exact 
test as the predictive score. For specific types of functions, AUC of 0.81 is achieved for 
Mendelian diseases, 0.74 for GWAS phenotypes, 0.85 for pharmacogenetic pathways, 0.76 for 
GO biological processes, 0.76 for Reactome signaling and metabolic pathways, and 0.72 for GO 
molecular functions (see Fig. S6). The true performance is likely higher, given the function-target 
function mapping issue. 
 
Not only are target functions of TFs predictive of their known functions, the numbers of target 
functions (i.e. multi-functionality) are also predictive of the numbers of known functions (Wald t 
statistic 6.07, p-value 3.1 × 10-9; or Wald t statistic 5.07, p-value 6.3 × 10-7 after controlling for 
the number of target genes per TF).  
 
We manually validated the TF-target function relationships for Mendelian diseases, GWAS 
phenotypes, and pharmacogenetic pathways, for which solid genetic evidence such as direct 
mutation of the TF in patients are available. 
 
Mendelian Diseases Targeted by Transcription Factors 
We identified the target Mendelian diseases of a TF based on the enrichment of disease causing 
genes (Hamosh et al. 2005) in the target genes of the TF. In total 181 TF - target Mendelian 
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disease relationships were identified at false discovery rate of 0.05. The majority of the top 
twenty TF-Mendelian disease associations (from thirteen TFs) are supported by direct genetic 
evidence such as mutations of the TF in the target Mendelian disease, GWAS associations 
between the TF and closely related diseases, or phenotypes closely related to the target disease as 
observed in mouse knockout models of the TF (Table 1).  
 
For example, we identified porphyria as a target disease of GATA1 (odds ratio 170, p-value 9.8 x 
10-9), while direct mutation of GATA1 (R216W) has been reported in a congenital erythropoietic 
porphyria patient (Phillips et al. 2007), and the mutant was suggested to cause the disease by 
regulating UROS, a common causal gene of congenital erythropoietic porphyria. We identified 
hereditary mitochondrial metabolism disease as a target disease of NHF4A, while it has been 
reported that HNF4A is mutated in hereditary noninsulin-dependent diabetes mellitus (NIDDM) 
(Hani et al. 1998), which is a mitochondrial disease. HNF4A is also mutated in maturity-onset 
diabetes of the young (MODY1) (Wang et al. 2000), and the MODY1 mutant form of HNF4A is 
known to cause mitochondrial function defects as well as impairment of nutrient-stimulated 
insulin release. Transcription factor SOX10 is predicted to be associated with Waardenburg's 
syndrome (Table 1) as well as Hirschsprung's disease and megacolon (not shown). Notably, 
SOX10 is a known causal gene of Waardenburg's syndrome type 4C and Hirschsprung’s disease 
(Pingault et al. 1998), while megacolon is a symptom of Hirschsprung’s disease. Another 
example is the association of RFX2 with Bardet-Biedl syndrome (BBS), which is a pleiotropic 
recessive genetic disorder belonging to a group of diseases called ciliopathy (Hildebrandt et al. 
2011). There are at least sixteen known BBS causing genes (or nineteen according to OMIM) 
covering around 80% of the diagnosed cases (Forsythe and Beales 2013). These BBS causing 
genes encode proteins involved in cilia biogenesis and function. Transcription factor RFX2 is not 
known to mutate in BBS patients, however, RFX2 together with RFX3 and RFX4, are key 
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regulators of cilia genesis in mouse and other animal models (Bisgrove et al. 2012; Chung et al. 
2012). 
 
In addition to above examples for GATA1, HNF4A, SOX10 and RFX2, other target Mendelian 
diseases among the top twenty are directly supported by human or mouse phenotypes upon direct 
mutation of the TFs. They are heart septal defect and congenital heart diseases for CTBP2, heart 
septal defect for SUZ12 (Fig. 3C), cancers for ETS1 and TP53, and inherited metabolic disorder 
for USF1. 
 
Complex Phenotypes Targeted by Transcription Factors 
We identified twenty significant complex phenotypes for seven transcription factors (Table S3). 
Transcription factors NFKB1 and RFX5 (Fig. 3D) are each associated with three and six 
autoimmune disorders, while both TFs are known to be involved in autoimmunity (Baeuerle, 
Patrick A. 1997; Masternak et al. 2000, 1998). Especially, NFKB1 is recently identified as a 
causal gene of autosomal dominant variable immunodeficiency-12 (Fliegauf et al. 2015), which 
shows features of autoimmunity. NFKB1 is also genetically associated with autoimmune disease 
Ulcerative colitis (Jostins et al. 2012). RFX5 mutations cause Bare lymphocyte syndrome II 
through impaired MHC II protein expression (DeSandro et al. 1999; Reith and Mach 2001), while 
MHC II is genetically linked to multiple autoimmune diseases (Fernando et al. 2008).  SREBF1 
(sterol regulatory element binding transcription factor 1) is identified to target blood LDL (low 
density lipoprotein) level (p-value 2.2 × 10-6), and not surprisingly, SREBF1 is a known regulator 
of LDL proteins and genes involved in sterol synthesis (Brown and Goldstein 1997; Shimano et 
al. 1997). Consistently, SREBF1 is associated with the statin pharmacodynamics pathway 
(PharmGKB) and multiple biological processes and pathways related to lipid metabolism. The 
SREBF1 LDL association is also directly supported by mouse mutation phenotypes (Hua et al. 
1996; Shimano et al. 1997). 
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Habitual coffee consumption is a significant target phenotype of AHR (Aryl hydrocarbon 
receptor, Fig. 3E), while AHR gene locus itself is also strongly associated with coffee 
consumption and habitual coffee consumption in GWAS studies (Cornelis et al. 2011, 2015; 
Sulem et al. 2011). HNF1A (Fig. 3G) targets three phenotypes, including the serum cell-free 
DNA level as an indicator of cardiovascular disease risk, serum bilirubin levels as a measure of 
cholelithiasis risk, and F-cell levels as an indicator of sickle-cell anemia. The first two phenotypes 
are validated by genetic evidence. HNF1A mutation is associated with elevated risk of 
cardiovascular diseases in diabetes patients (Steele et al. 2010) while SNPs of HNF1A is found to 
be associated with cardiovascular disease risks in young and old European Americans (Reiner et 
al. 2009). The HNF1A-cholelithiasis connection is supported by HNF1A knockout mouse 
(Pontoglio et al. 1996), which showed elevated blood bilirubin levels and jaundice. Consistently, 
HNF1A also targets Reactome pathway synthesis of bile acids and bile salts (Fig. 3G). 
 
Pharmacogenetic Pathways Targeted by Transcription Factors 
We identified 99 TF-target pharmacogenomic pathway relationships, covering 47 unique TFs and 
45 unique pharmacogenetic pathways in PharmGKB. There is no preference towards 
pharmacokinetics (PK) or pharmacodynamics (PD) pathways, with 20 of 40 PK pathways and 26 
of 50 PD pathways identified.  However, different TFs are responsible for the target PK and PD 
pathways. 18 of the 26 target PK pathways are the targets of just 4 TFs (see Table S4), i.e. 
HNF1A, AHR, NR1I3, and FOXA2. Among them, nuclear receptor genes HNF1A, AHR, and 
NR1I3 are well known to regulate xenobiotic-metabolizing enzymes (Pontoglio et al. 1996; 
Sogawa and Fujii-Kuriyama 1997; Lamba et al. 2005; Ma 2008). Unique target PK pathways are 
found for each of the four TFs, suggesting their complementary roles in regulating drug 
metabolism. In addition to these 4 TFs, SP1 and TP53 are each associated with 3 PK pathways 
for cancer drugs. SP1 and TP53 are also associated with other cancer PD pathways, and their 
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associations with cancer are strongly supported by the literature (Li and Davie 2010; Hollstein et 
al. 1991). 
 
We manually examined the full list of identified target PD pathways and confirmed majority of 
the associations (see Table S4). A PD pathway describes the disease pathway that is perturbed by 
a drug. A target PD pathway is considered confirmed if the TF is a member of the PD pathway or 
closely related pathways, or if the TF is known to be genetically linked to the disease or closely 
related phenotypes. For example, ELK1 is identified as a regulator of the EGFR Inhibitor 
Pathway, while the TF itself is a member of the PD pathway. HNF1A is identified as a regulator 
of the PD pathways for cancer, high cholesterol, and diabetes, while mutations of HNF1A is 
known to cause hereditary cancers and diabetes, and variants of HNF1A are strongly associated 
with cholesterol level in GWAS (Teslovich et al. 2010). E2F1 and E2F4 are identified for 
multiple antimetabolite PD pathways. Antimetabolites are a class of drugs for inducing medical 
abortions and treating cancers and autoimmune diseases through halting the cell cycles, while 
E2F1 and E2F4 are well-known regulators of cell cycles (Ren et al. 2002; Gaubatz et al. 2000).  
 
Target Gene Sharing among Transcription Factors 
While the target genes of a transcription factor define its biological functions, the target gene 
sharing between two TFs also reflects the functional relatedness between TFs. We studied the 
relationship between the target gene overlaps and target function sharing between pairs of TFs. 
 
As expected, the target gene sharing, measured by Pearson’s phi coefficient 𝜙!" , is highly 
associated with the target function sharing 𝜙!"#$%&  !"# (Wald T-statistic 126.95, or 109.75 when 
controlling for the number of target genes, both p-values < 2.2 × 10-16). Among 73,536 possible 
TF pairs (Fig. S7), 12,434 (16.9%) show significant target gene sharing at false discovery rate of 
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0.01 based on Fisher’s exact test. We refer to these similar TFs as TF neighbors. Relatedly, there 
are 11,205 pairs of TFs with one or more shared target functions, including 5,866 pairs that also 
show significant target gene sharing (odds ratio 9.3).  
 
Despite the overall consistency between target function overlap and target gene sharing, many 
exceptions occur. Significant target gene sharing was observed for 6568 pairs of TFs that did not 
share any target functions, including 428 pairs that surprisingly showed negative correlations 
between their target function association profiles1. This could be caused by unknown or poorly 
understood functions common to these TF neighbors, and it suggests that the target gene-based 
TF neighbors may provide functional information missed by the target functions, therefore, the 
TF neighbors serve as an additional layer in the TF function annotations. On the other hand, 
significant target function sharing (at FDR < 0.05) is observed for 329 pairs of TFs that have 
lower-than-expected target gene overlaps. The top five TF pairs by target function sharing are 
MXI1 and RFX1, TRIM28 and VDR, LMO2 and ZNF263, ARNTL and BHLHE40, ETV5 and 
MXI1. Among these, two pairs, TRIM28 and VDR, ARNTL and BHLHE40, do not share any 
target genes. However, TRIM28 and VDR (Vitamin D Receptor) share 12 target functions, e.g. 
Reactome Telomere Maintenance, out of 15 and 14 target functions for the two TFs respectively; 
while ARNTL and BHLHE40 share 2 target functions, Reactome Bmal1 Clock Npas2 Activates 
Circadian Expression and Reactome Circadian Clock, out of 4 and 2 target functions for the two 
TFs respectively. Mouse gene knock out confirmed the abnormal circadian rhythm as a 
phenotype for both ARNTL (Bunger et al. 2000; Storch et al. 2007) and BHLHE40 (Rossner et al. 
2008), and the two proteins may be interaction partners (Honma et al. 2002). 
 
                                                
1 The target function association profile of a TF is comprised of the Pearson’s phi coefficients between the TF and all 
3715 functional concepts. A lack of positive correlation between two profiles indicates that the two TFs are likely 
functionally unrelated based on the known functional concepts.  
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Transcription Factors Link Apparently Unrelated Functions: Coffee and Warfarin 
Parallel to the TF target gene sharing and TF target function sharing, we observed extensive 
member gene overlaps and regulator sharing between pairs of functional concepts (see 
Supplemental Material Section 1.3). Majority of TFs (64%) have two or more target functions. 
We observed that apparently unrelated gene functions are frequently linked by transcription 
factors. For example, AHR is found to be associated with coffee consumption, the PK pathways 
for drugs Amodiaquine, Warfarin, Erlotinib, and Phenytoin, as well as the estrogen metabolism 
pathways (Fig. 3E). Based on these observations, we hypothesize that coffee consumption would 
interfere with the metabolism of these drugs and estrogen, either through modifying the activities 
of AHR target enzymes or impacting the expression of the enzyme genes through feedback 
regulation of AHR activity. The interactions of coffee drinking with both Warfarin (Zambon et al. 
2011) and Phenytoin (Wietholtz et al. 1989) have been reported. On the other hand, coffee 
consumption is actually associated with decreased venous thromboembolism (Enga et al. 2011), 
which warfarin can effectively treat. The coffee-estrogen link is even more intriguing. High 
coffee intake is found in multiple studies to be significantly associated with decreased risk of 
estrogen-receptor negative breast cancer (Li et al. 2011; Lowcock et al. 2013) and breast cancer 
risk in BRCA mutant carriers (Nkondjock et al. 2006). In addition, high coffee intake impacts the 
risk of Parkinson’s disease in female in an estrogen dependent manner (Ascherio et al. 2003, 
2004), possibly through modifying blood estrogen levels (Nagata et al. 1998). 
 
Obviously, when two functional concepts are statistically associated, i.e. when they share 
significant number of member genes, they will likely be linked to the same regulators (Fig. 4A 
and Fig. S9A). The inverse is however not true. Two functions can be linked by transcription 
factors even when they do not share significant portion of member genes (Fig. 4B and Fig. S9B).  
In fact, of the 954 function pairs that share identical sets of regulators, 356 (37%) pairs have less 
gene overlap than expected by chance (Table S7), i.e. with odds ratio < 1. Most of such function 
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pairs do not share any member genes. For example, hereditary “lipid storage diseases” do not 
share any genes with Reactome pathways “iron uptake and transport” and “insulin receptor 
recycling”, but the 3 functions are found to share regulators ATF3, NFE2, USF1, and USF2, 
while “iron uptake and transport” is also a target function of ARNT (Fig. 4C). Other examples 
include ventricular septal defect and developmental pattern specification process which are both 
targeted by SUZ12 and CTBP2, PECAM1 Interactions and disease agammaglobulinemia targeted 
by EBF1, intestinal disease and Human immunodeficiency virus infectious disease both targeted 
by NFKB1, prostate cancer and intestinal cancer both targeted by TP53, Metalloendopeptidase 
Activity and cognitive disorder both targeted by ETV4, among many others. 
 
Measuring the Functional Pleiotropy of Transcription Factors 
A transcription factor is functional pleiotropic if it targets multiple unrelated functions. The above 
analyses suggest extensive functional pleiotropy for transcription factors. Here, we quantify the 
functional pleiotropy of TFs in order to further study its causes from the perspective of 
transcriptional regulation. The number of target functions 𝑛!"#$%&  !"# can be a measure of TF 
functional pleiotropy, with the caveat that it double counts closely related or redundant functional 
concepts. We hence define function diversity 𝜋!"#$%&  !"# as the “effective” number of target 
functions by weighting each function by its uniqueness, which is the inverse of the accumulative 
similarity between the function and other functional concepts. Similarly, we define regulator 
diversity 𝜋!"# of a gene as the effective number of regulators. The regulator diversity corrects for 
related or cooperative transcription factors that are counted independently in the number of 
regulators 𝑛!"# targeting a gene (see Methods and Supplemental Material Section 1.4 for details).   
 
The two most functional pleiotropic TFs are BRCA1 and ZNF143. They are annotated with 272 
(45.5 effectively) and 242 (35.4 effectively) target functions, and 101 (14.5) and 22 (2.8) known 
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functions, while regulated by 33 (15.9) and 53 (22.1) upstream TFs respectively. The two TFs of 
the highest upstream regulatory diversity are MYC and TP53. They have 50 (25.1) and 49 (23.0) 
regulators, and are annotated by 159 (24.2) and 175 (26.8) target functions, and 68 (12.4) and 166 
(25.4) known functions respectively. By contrast, TFs with smaller number of target functions 
also tend to have fewer upstream regulators. For example, HNF1A has 9 (3.8) regulators, 30 (6.3) 
target functions, and 58 (11.2) known functions (Fig. 5A); NFKB1 has 26 (11.7) regulators, 143 
(23.7) target functions, and 34 (6.2) known functions (Fig. S11A); SUZ12 has 11 (4.9) regulators, 
48 (8.3) target functions, and 4 (1.0) known functions. Fig. 6 provides the target gene-based 
function annotations for TFs NFKB1 and SUZ12, including the target functions, TF 
neighbors, as well as the function diversity measures. 
 
Upstream Regulation Enables Functional Pleiotropy of Transcription Factors 
Over the set of 384 TFs in the TFTG compendium, we observed a global positive association 
between the target function diversity of TFs with the regulator diversity (Wald test p-value 3.3 × 
10-10 between diversity measures 𝜋!"#$%&  !"# and 𝜋!"#; or p-value 1.6 × 10-9 between raw counts 𝑛!"#$%&  !"# and 𝑛!"#), i.e. TFs with more effectively-unrelated upstream regulators also tend to 
have more effectively-unrelated target functions. This suggests diverse modes of upstream 
regulation as a mechanism for TFs to realize functional pleiotropy. To eliminate technical biases 
due to ChIP-seq experiment quality or uneven research attention for different TFs, we controlled 
for 𝑛!" , the number of target genes per TF, as a confounding factor through linear model. 
Regulator diversity however remained a significant predictor of TF’s function diversity (p-value 
5.3 × 10-6 , Wald test). Further, we examined the known functions of TFs, which, unlike the target 
functions, are independent of the TFTG data compendium. A significant association remained 
between the known function diversity and the regulator diversity of TFs (p-value 6.3 × 10-5 
between diversity measures 𝜋!"#$"  !"# and 𝜋!"#, or p-value 0.00022 between raw counts 
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𝑛!"#$"  !"# and 𝑛!"#). This was true regardless of the number of target genes for the TFs. In fact, 
slightly stronger correlation was observed when TFs with less than 100 target genes were 
removed (Fig. S12). Finally, to completely eliminate the impact of human research biases toward 
popular TFs, which could result in higher number of literature-reported target genes as well as 
literature-reported upstream regulators for the popular TFs, we repeated the above all experiments 
after removing all low-throughput (literature derived) data in the TFTG compendium. We 
observed that regulator diversity and function diversity remain significantly associated (see 
Supplemental Material Section 1.5).  As a control, we evaluated the association between TF’s 
Functional Pleiotropy and its hierarchical location within the gene regulatory network, measure 
by PageRank (Page et al. 1999). Neither the PageRank-function diversity nor the PageRank-target 
function diversity associations are significant after controlling for the number of target genes of 
TFs (see Supplemental Material Section 1.6).  
 
In addition, we observed that the positive association was universal for all six types of function 
annotations. The trends are stronger for biological processes and molecular pathways, and weaker 
for GWAS and disease phenotypes (Fig. 5B). The association between function and regulator 
diversities extends to non-TF genes as well, with p-value 7.9 × 10-5 between diversity measures 𝜋!"# and 𝜋!"# and p-value 3.0 × 10-18 between raw counts 𝑛!"# and 𝑛!"# for 11345 genes that 
have both regulator and function annotations (see Supplemental Material Section 1.7).  
 
If regulator diversity is indeed a cause of TF function diversity, it is likely through driving the 
expression of the TF in diverse conditions. To evaluate this mechanism, we examined the 
expression of transcription factors in a collection of 327 human tissue types and cell lines 
(McCall et al. 2011). As expected, expression diversity of TFs is significantly associated with the 
regulator diversity (Spearman rank correlation 0.22, p-value 2.7 × 10-6, or Spearman rank 
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correlation 0.26, p-value 3.6 × 10-7 for the raw counts). On the other hand, there is a significant 
association between expression diversity of TFs and the target-function diversity (Spearman’s 
rank correlation 0.10, p-value 0.048), and the function diversity (Spearman’s rank correlation 
0.26, p-value 2.2× 10-7). Similarly, we observed strong associations between expression diversity 
of general genes and the function and regulator diversities of genes (see Supplemental Material 
Section 1.7). These support transcriptional regulation diversity as a mechanism for functional 
pleiotropy of transcription factors and other genes. 
 
Discussions 
A major challenge in data-driven TF function annotation is to minimize the impacts from false 
bindings and to reliably extract gene function signals. We combined multiple statistical strategies 
to achieve this. First, we target genes from ChIP-seq experiments are extracted with a stringent 
false discovery rate (FDR), which is calculated using a statistical framework modified from TIP 
(Cheng et al. 2011a) that combines binding locations and intensity information to differentiate 
true TF-DNA binding events from false signals. Second, we define the target functions of TFs as 
the consensus functions among the putative target genes. The statistical enrichment analysis 
hence further filters noises from the remaining false target genes. Third, we choose conservative 
gene universes specific to the types of functions, so as to minimize spurious associations. Finally, 
we apply the Benjamini–Hochberg multi-test correction procedure and require a FDR of 5% for 
all associations we report. With these, around 10K significant TF-target function associations are 
obtained. Meanwhile, the total number of true TF-target function associations is estimated to be 
over 80K, indicating the presence of rich functional signals in the TFTG data (Fig.3). We believe 
there is room for further improvement to retrieve higher number of TF-target function annotations 
at controlled false discovery rate.  
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We globally validate the TF-target function associations by comparing them with known TF-
function relationships, and show that the target functions cover both known and novel TF-
function relationships. Despite the fact that TF-target function and TF-function relationships do 
not always have direct correspondence, we observe a good prediction performance with AUC 
0.80 with 6 types of gene functions combined. In addition, we manually validate the top target 
diseases, phenotypes, and pharmacogenetic pathways based on the literature, and find that 
majority of them are supported by direct genetic evidence, such as direct mutations or GWAS 
implicated associations of a TF in patients with the target disease, or phenotypes of mouse knock-
out models of the TF (Table 1, S3 and S4), even when they are not annotated as known function 
of the TFs. Given that our knowledge is incomplete for even the most well studied TFs, we 
believe the non-validated TF-target functions represent opportunities for future experimental 
studies of the TFs.  
 
The foundation of this study is the hypothesis that genes regulated by a same TF are functionally 
related. We believe this extends to the functional concept level, i.e. multiple concepts targeted by 
the same TF(s) are also functionally related at some higher level. Based on co-regulation, we 
predict the interaction between coffee consumption and the metabolism of multiple drugs 
including warfarin as well as the interaction between coffee consumption and estrogen 
metabolism, both of which are validated by multiple published experimental studies (Wietholtz et 
al. 1989; Zambon et al. 2011; Enga et al. 2011; Li et al. 2011; Lowcock et al. 2013; Nkondjock et 
al. 2006; Ascherio et al. 2003, 2004). Further, we show that TFs link hundreds of functional 
concept pairs that do not share any member genes. This highlights the potential usage of the TF-
target function network to study the high-level organization principles among biological functions 
that is unattainable by solely studying the member genes of functions, e.g. through a member 
gene-based function-function association network.  
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Based on the TF-target function network, we examine the functional pleiotropy of TFs. We 
discover that a TF with more target functions (or known functions) are themselves regulated by 
significantly more TFs, and both function and regulator diversities are associated with the 
expression diversity of the TF in cell lines and tissues. These suggest that regulator diversity may 
be a cause of function diversity of TFs, and it works by driving the expression diversity of genes. 
 
Gene regulation is well known to be cell type specific, and co-expression of TFs is required for 
the co-regulation of TFs on the shared target genes (Ravasi et al. 2010). However current high-
throughput studies for in-vivo TF-DNA binding, including the ENCODE project (Wang et al. 
2013; Gerstein et al. 2012), are generally limited to a small number of tissue/cell types. 
Comprehensive ChIP-seq analysis on a large number of cell types remains unrealistic due to cost 
and resource requirements. We hence compile the transcription factor - target gene relationships 
in a cell type and development stage agnostic manner. Contingent on data availability, this work 
can be easily extended to perform cell type specific TF function annotation. Despite this 
compromise, the resulting TFTG data turns out to partially capture  the cell type specificity of 
TFs, as we observe TFs sharing similar tissue expression patterns also share greater amount of 
target genes (Wald T-test, p-value 1.9 × 10-78). 
 
In an effort to manually annotate TF functions, (Yusuf et al. 2012) teamed up over 100 experts to 
curate and integrate published knowledge and provide mini-reviews on transcription factors. We 
believe automated yet accurate function annotation and manual curation are complementary and 
will together greatly facilitate our understanding of the biological functions of human 
transcription factors.  
 
Despite large consortium efforts such as ENCODE (Bailey et al. 2013; Gerstein et al. 2012), 
existing data for transcription factor-target gene relationships remains scarce. Our TFTG 
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compendium covers 384 unique transcription factors. This is the largest collection to our 
knowledge, as compared to 237 TFs in a recently published study (Griffon et al. 2015), yet this 
only covers 20-25% of the putative 1500-2000 transcription factors in human (Vaquerizas et al. 
2009; Kummerfeld and Teichmann 2006). Relatedly, we notice that the TFTG compendium is 
biased toward the well-known transcription factors, likely due to preferential attachment of 
research efforts to popular TFs. For the same reason, some TFs enjoy higher target gene coverage 
than the other TFs. These biases currently limit the power of target gene based TF function 
annotation. However, with the maturity of ChIP-seq and related high-throughput assays for in-
vivo protein-DNA binding and the availability of the technologies to more labs, we expect a stead 
accumulation of TFTG data with improved accuracy and completeness yet reduced biases. Such 
data will ultimately enable the annotation of all transcription factors in the human genome, and 
serve as the foundation for hypothesis generation and further experimental studies of the roles of 




Transcription Factor Target Gene Data Compendium 
We compiled transcription factor-target gene (TFTG) relationships from multiple sources. ChIP-
seq experiments from both large-scale (Bernstein et al. 2012; Gerstein et al. 2012; Yan et al. 2013) 
and small-scale studies were included. Meta-data of 413 ChIP-seq experiments for 235 unique 
transcription factors were curated manually (by October 2013) from GEO (Barrett et al. 2013), in 
addition to around 450 ChIP-seq experiments for 115 unique transcription factors from the 
ENCyclopedia of DNA elements (ENCODE) (Bernstein et al. 2012; Gerstein et al. 2012). 
Manually curated low-throughput target gene annotations were compiled from multiple databases, 
including BIND, HTRI, PAZAR, and TRED (Bader 2003; Bovolenta et al. 2012; Portales-
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Casamar et al. 2009; Jiang et al. 2007). Only TFTG relationships with direct literature evidence 
from low throughput experiments (Yang 1998; Geertz and Maerkl 2010), e.g. as electrophoretic 
mobility shift assays, were included. We did not differentiate sequence specific DNA-binding 
transcription factors from other DNA binding transcriptional regulators. Some cofactors that do 
not directly bind DNA are also included when there are ChIP-seq data available. Despite this, we 
refer to all these transcriptional regulators as transcription factors (TFs) in this study. The binding 
signals from target genes were differentiated from that from non-target genes using a modified 
version of the TIP algorithm (Cheng et al. 2011a), which combines the binding location and 
intensity information for scoring TF target genes (See Supplemental Methods section 2.1).   
 
Gene Function Annotation Data 
Six types of gene annotations were used in this analysis to annotate transcription factors. Gene 
Ontology (GO) (Ashburner et al. 2000) for biological processes (BP) and molecular functions 
(MF), together with the Reactome pathways (Joshi-Tope et al. 2005) were retrieved from the 
MSigDB v4.0 (Liberzon et al. 2011). The Pharmacogenomics pathways for pharmacodynamics 
(PD) and pharmacokinetics (PK) were retrieved on Jan. 20, 2013 from the Pharmacogenomics 
Knowledgebase (PharmGKB) (Hewett 2002). Gene disease association data from genome wide 
association studies (GWAS) were obtained on May 4, 2014 from dbGAP (Mailman et al. 2007) 
and NHGRI (Welter et al. 2014) catalogs with p-value cutoffs at 1E-3 (loose set) or 1E-5 
(stringent set), and the closest gene, or two genes if the SNP is intergenic, to each SNP is retained. 
When not specified, the loose set is used. Note here a large p-value cutoff is used to capture 
majority of the true disease related genes rather than to select for confident ones, as our goal here 
is to associate complex phenotypes and diseases rather than individual genes with transcription 
factors. The gene - Mendelian disease annotations were obtained on July 5, 2014 from the Online 
Mendelian Inheritance in Man (OMIM) (Hamosh et al. 2005), and the disease genes were further 
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grouped in a hierarchical manner to disease classes based on the disease ontology (Schriml et al. 
2012). For all data, only genes uniquely mapped to the Entrez Gene database (Maglott et al. 2005) 
are retained.  
 
Defining Coding Genes and Literature Rich Genes 
Coding genes are defined as all Entrez genes that have associated protein products in Ensembl 
Protein or UniProt databases. Literature Rich genes are defined as coding genes annotated in any 
of the following 7 data sources: GO Biological Processes, GO Molecular Functions, Reactome, 
PharmGKB, Kyoto Encyclopedia of Genes and Genomes pathways(Kanehisa 2000), 
Biocart(Nishimura 2001), and OMIM(Hamosh et al. 2005). There are 19847 Coding and 10931 
Literature Rich genes in total. Interestingly, 333 of the Literature Rich genes are not Coding 
genes, but pseudogenes, discontinued gene records, or gene loci without defined genes. These 
were removed, leaving 10561 Literature Rich genes in total.  
 
Measuring the Associations between Binary Variables 
Fisher’s exact test (Mehta 1986) is used for testing the associations between transcription factors 
and biological functions, by detecting significant enrichment of genes that are target genes of a 
TF and are also annotated with a given function. G-test is used as a fast approximation to Fisher’s 
exact test in preliminary analyses and to demonstrate the presence of functional signals in the TF 
target gene data (Figure 3). To perform multi-test correction, we calculated the Benjamini-




Since Fisher’s exact test does not have a test statistic that we can use to measure the similarities 
between two binary variables. We use Pearson’s phi coefficient (𝜙, PPC) to measure association 
strength, 
!! !!!!!!!!!"!!"!!"!!!! !!!!!!" !!"!!!! !!!!!!" , 
where 𝑛!" are the observed number of 𝑖𝑗 value pairs for the two random variables. The strengths 
of TF-Function association, TF-TF target gene sharing, TF-TF target function sharing, TF-TF 
known function sharing, and Function-Function member gene sharing are denoted as 𝜙!"_!"#, 𝜙!" , 𝜙!"#$%&'(), 𝜙!"#, and 𝜙!"#_!!" respectively. PPC is sample size independent, and serves 
as a good measure of the magnitude of associations. The sign of PPC indicates the directionality 
of an association.  
 
Functional and Regulator Diversities of Transcription Factors  
We measure the effective number of transcription factors (i.e. the regulatory diversity) of a 
function or gene and the effective number of target functions (i.e. the function diversity) of a TF 
by down weighting the TFs (or functions) that are correlated with other TFs (or functions). Given 
Pearson’s phi coefficient 𝜙!!! between TFs 𝑡 and 𝑡!, the uniqueness of TF 𝑡 is defined as 𝑢! = 1/ 𝜙!!!!!!∈!"# . Note that 𝑢! is always within 0 to 1, since the association between a TF 
with itself is always 1, i.e. 𝜙!!! = 1.  The regulator diversity 𝜋!"#.! of a function or gene 
(including TF) 𝑔 is then defined as the weighted counts of the transcription factors targeting the 
function or gene, 𝜋!"#.! = 𝑢!!∈!"#  !"#$%&'()#  ! . The regulator diversity measures the effective 
(non-redundant) number of regulators for a gene (or a TF). Similarly we can define the 
uniqueness of each function annotation term, phenotype, or disease, and then define the target 
function diversity 𝜋!"#$%&  !"# (i.e. effective number of target functions) of a transcription factor 




The Cytoscape file for the full TF-function network is available at simtk.org under identifier 
TFAnno and the full target function annotations for TFs are available as supplemental Table S7. 
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Figure Legends 
Figure 1:  
An outline of the workflow for regulatory network based annotation of transcription factor 
functions. 
 
Figure 2:  
Presence of gene function signals in the TFTG data. The scatter plot shows the p-values of 
function-TF associations obtained using real TFTG compendium (x-axis) and a fake TFTG 
compendium (y-axis). Each dot corresponds to a pair of p-values for a TF-Function pair. The inlet 
shows the number of significant TF-Target Function relationships at varying p-value cutoffs for 
the real TFTG data (y-axis) against the number for the fake TFTG data (x-axis). P-values are 
obtained by G-tests. 
 
Figure 3:  
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(A) Global view of the transcription factors and their target functions. 311 TFs and 1420 
annotations with one or more significant associations at FDR 0.1 levels are retained. Red 
indicates positive associations, green indicates negative associations, white indicates FDR > 0.1. 
Intensity of the colors corresponds to the significance levels: FDR 0.1, 0.05, and 0.01.The TF and 
target function clustering showed on the left and top was performed based on the TF-target 
function association phi coefficient matrix. We used the literature rich gene universe for the 
association analysis except for the TF-GWAS phenotype association, for which the coding gene 
universe is used.  
(B) The network visualization (Smoot et al. 2011) of TF-target function and TF-known function 
relationships. Edges are colored red or green the same way as in (A). A solid edge links a TF with 
a significant target function that is not a known function. A dashed edge links a TF with a known 
function. A dashed edge with color links a TF with a known function that is also a significant 
target function, while a grey dashed edge links a TF with a known function that is not a 
significant target function. Node colors and shapes correspond to function types: purple circles, 
TFs; grey rectangles, Reactome pathways; blue triangles, GO molecular functions; white 
diamonds, GO biological processes; red rhomboids, PharmGKB PK and PD pathways; yellow 
hexagon, Mendelian diseases; green octagons, GWAS phenotypes.  
 
Figure 4:  
Transcription factor sharing among apparently unrelated functional concepts. (A) Two functional 
concepts with high member gene overlaps always have similar regulators, but (B) two functional 
concepts with nearly identical regulators do not always have high member gene sharing. (C) A 
Venn diagram for 3 functional concepts for which shared transcription factors are identified for 
functions without gene overlaps. The arrows connect the significant regulators for the functions. 
Note that “Iron Uptake and Transport” and “Insulin Receptor Recycling” do share member genes 
significantly, but neither of them shares member genes with “Lipid Storage Disease”. 
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Figure 5:   
The relationship between functional diversity and regulator diversity of transcription factors. 
(A) The target functions of transcription factor HNF1A form 3 major clusters based on 
similarities (member gene sharing) among the functions, while the upstream regulators of 
HNF1A form clusters based on the functional similarities (target gene overlaps) among these 
regulators. The regulator and functional diversities of a gene measures the effective number of 
regulators and effective number of functions for a gene. The coloring schema is same as in Figure 
5 and the clustering of TFs and functions are based on the TF’s target gene overlaps and 
function’s member gene overlaps. 
(B) Significant associations exist between the regulator diversity and target function diversity of 
transcription factors for six types of function annotations separately.  
 
Figure 6:  
Complete target gene-based annotations for two example transcription factors (A) NFKB1 and (B) 
SUZ12. Three types of information are provided: 1) the top TF neighbors obtained by TF distance 
(1- target-gene overlap measured by Pearson’s phi coefficient) < 0.8; 2) the target functions in six 
categories, 3) the functional diversities in six categories and total diversity. See Figure S9 for a 




























Disease: viral infectious disease
Disease: inflammatory bowel disease
Disease: acquired immunodeficiency 
syndrome 
























































































































Disease: primary immunodeficiency disease
Disease: B cell deficiency
Disease: agammaglobulinemia
Disease: blood protein disease






Disease: disease by infectious agent
Disease: viral infectious disease
Disease: Human immunodeficiency virus infectious disease




































































Disease: heart septal defect
Disease: congenital heart disease
Disease: tetralogy of Fallot
Disease: ventricular septal defect
Disease: double outlet right ventricle
Disease: autosomal dominant disease
Disease: genetic disease
Disease: monogenic disease














































































Disease: acquired metabolic disease
Disease: type 2 diabetes mellitus
Disease: diabetes mellitus
Disease: carbohydrate metabolism disease
Disease: glucose metabolism disease





















































































































































Disease: hypersensitivity reaction type IV disease









































Disease: reproductive organ cancer
Disease: prostate cancer


















Disease: disease of cellular proliferation




































































































































































































































Disease: endocrine gland cancer






































































































































































































Disease: bone marrow disease
Disease: Diamond−Blackfan anemia











































































































Disease: disease of metabolism
































































Disease: immune system disease
Disease: hematopoietic system disease
Disease: hemorrhagic disease
Disease: blood platelet disease
Disease: blood coagulation disease




















































































































Disease: lysosomal storage disease




















Disease: gastrointestinal system cancer
Disease: colorectal cancer
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Disease: hypersensitivity reaction 




















Disease: connective tissue cancer
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Disease: thyroid gland disease
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Table 1. Top twenty TF – target disease associations. The “Literature Rich” gene universe is used 
for the association detection. Log2(OR), log2 transformed odds ratio; P-value: p-value from 
single-tailed Fisher’s exact test for odds ratio > 1; Evidence: lists published genetic evidence 
directly support the association of the TF with the disease;  Mutation: mutations of the TF are 
observed in the disease or closely related diseases. Association: The TF gene locus is genetically 
associated with the disease or related diseases. Mouse: mouse model shows phenotypes directly 
related to the disease. Non-genetic evidence in the literature is not considered. MODY1: 
maturity-onset diabetes of the young. FCHL: familial combined hyperlipidemia.  
 
TF Target Disease log2(OR) P-value Evidence 
ATF3 Lysosomal storage disease 4.5  3.9E-09 - 
BRCA1 Mitochondrial metabolism disease 3.1  3.7E-09 - 
CTBP2 Heart septal defect 













ETS1 Organ system cancer 2.6  1.2E-08 Mutation 
(Seth and 
Watson 2005) 
GATA1 Acute porphyria 7.4  9.8E-09 Mutation(Philli
ps et al. 2007) 
HNF4A Mitochondrial metabolism disease 3.0  5.3E-09 Mutation in 
MODY1 
(Wang et al. 
2000) 
NFE2 Lysosomal storage disease 







RFX2 Bardet-Biedl syndrome 5.5  1.1E-12 Mouse 
(Bisgrove et 
al. 2012; 
Chung et al. 
2012) 
SOX10 Waardenburg's syndrome 11.4  2.0E-09 Mutation 
(Pingault et 
al. 1998) 
SUZ12 Heart septal defect 6.2  7.4E-09 Mouse (He et 
al. 2012) 
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TP53 Organ system cancer 
Cancer 
Disease of cellular proliferation 













et al. 1990) 
USF1 Disease of metabolism 











USF2 Lysosomal storage disease 
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1. Supplemental Results 
1.1. Negative Associations between Transcription Factors and Functions 
Overall, 279 (73%) transcription factors are annotated by at least one functional term, while 
around 27% (103) transcription factors are annotated at least once by negatively associated gene 
functions or phenotypes. Percentage of negative TF association is lowest for pharmacogenomic 
pathways (2%) and Mendelian diseases (5%), and highest for GWAS phenotypes (51%) and gene 
molecular functions (40%). Many of the negative associations may simply indicate that the TFs 
and the function are irrelevant, although some of the negative TF-phenotype associations appear 
to be biologically meaningful. For example, NOTCH1 is negatively associated with myocardial 
infarction (OR = 0.47, Hypergeometric test p-value = 3.8 × 10-7), while NOTCH1 is known to 
mediate cardiac repair following myocardial infarction (Gude et al. 2008; Li et al. 2011). 
 
1.2. Transcription Factors have Preferences on the Type of Function Annotations 
We observed extensive TF sharing among the 6 types of gene functions (Fig. S5A).  
Meanwhile, we observed systematic preference of different types of TFs to different sources of 
gene functions. For example, HNF1A target functions are 53 fold enriched for PK/PD pathways, 
23 fold enriched for GWAS phenotypes, and 4 fold enriched for Mendelian diseases, while 
TCF12 target functions are 16 fold enriched for GO molecular functions, and 4 fold enriched for 
Reactome pathways. In total, there are 62 TFs with significant biases toward specific types of 
functions (Fig. S5B). We note that different types of gene annotations are focused on different 
levels or different aspects of functions in living organisms. The biases of TFs toward specific 
types of functions suggest some high-level architecture of the TF-target function network. 
Specifically, different TFs may be in charge of functions of different levels from molecular to 
phenotype. 
 
1.3. Transcription Factors Sharing Reveals Redundant or Related Functions 
From the TF-target function relationships, we observed extensive regulator sharing among the 
functional concepts (e.g. Cor pulmonale and primary pulmonary hypertension) as well as target 
function overlaps among transcription factors (e.g. CTBP2 and SUZ12 in Fig. 3B top left). 
Redundancies or associations among functional concepts from both same sources and different 
annotation sources are observed (Fig. 3B). One cause of the concept similarities is the built-in 
redundancy of functional concepts within sources such as Gene Ontology, which defines concepts 
hierarchically, and between sources such as the GO biological processes and Reactome pathways, 
both of which covers signaling pathways. Another cause is the inherent biological relatedness of 
apparently different concepts, such as beta-cell development and diabetes, both of which are 
identified as targets of KLF11 and PDX1 (Fig. 3B bottom left). 
 
We quantified the redundancy between functional concepts by their member gene overlap using 
Pearson’s 𝜙 coefficient, and estimated the total effective number of functional concepts to be 
1316 compared to the total of 3715. Relatedly, 954 pairs of functional concepts are regulated by 
identical set of TFs, and 141 pairs of concepts have identical member genes. GO biological 
processes have the highest redundancy of 3.7 fold, while the GWAS phenotypes have the lowest 
redundancies of 1.2 fold (Table S2). 
 
To further reveal the overall concept relatedness/redundancy between different sources of 
functional concepts, we calculated the average number of shared TFs per pairs of functional 
concepts from the 6 different sources (Fig. S5B). We find molecular functions, biological 
processes, and Reactome pathways cluster closely with >0.5 TFs shared per pair of functions 
from different sources, compared to 0.6-1.3 TFs shared per pair of functions from same sources). 
Pharmacogenomic pathways and Mendelian diseases form another cluster with 0.08 TFs shared 
per pair of functions from different sources, compared to 0.16 or 0.22 TFs shared per pair of 
functions from same sources.   
 
1.4. Basic Statistics of Functional Diversity and Regulator Diversity of TFs 
Overall, the average uniqueness of all functional concepts is only 0.4 (i.e. average degeneracy 
2.8). There are on average 23.9 target functions per TF, while the target function diversity is only 
3.7 with a degeneracy of around 6.1 fold, higher than the average degeneracy of all functions. On 
the other hand, the transcription factors are also highly related to each other, with an average 
uniqueness of 0.6, and effectively 226.0 functionally unique TFs out of 384. For each TF, there 
are 11.8 upstream regulators, while the regulator diversity is 5.2 and regulator degeneracy 2.2. 
Fig. 6A give an example of TF HNF1A, which have 6.3 effective target functions and 3.8 
effective regulators (see Fig. S11 for more transcription factors RXF5 and NFKB1; and also 
examples of non-TF gene MTHFR). 
 
1.5. Removing the impact of human research biases on the association between TF regulator 
diversity and function diversity 
The TFTG compendium contains TF-target gene relationships from the literature of low 
throughput studies. Such data are prone to human biases toward the perceived important TFs. 
These popular TFs can have more target genes as well as upstream regulators reported due to 
higher research efforts, hence creating an artificial association between the number of regulators 
and number of identified target functions. We corrected such biases by including the number of 
target genes of TF as a confounding variable (see main text). As a stricter validation, we 
completely removed the low-throughput data in the TFTG data, retained only the target genes for 
262 TFs from ChIP-seq studies, and redid all analyses. The selection of TFs in ChIP-seq 
experiment remains biased toward the well-known TFs. Popular TFs however should no longer 
have more upstream TFs due to preferred study of the regulators of these TFs. Despite a smaller 
number of TFs and a loss of the most reliable target genes for the remaining TFs, regulator 
diversity and function diversity remain significantly  associated (p-value 0.015, or 0.0086 when 
controlling for the number of target genes).  
 
1.6. Hierarchical location of a TF in the regulatory network is not associated with 
multifunctionality of the TF 
Aside from regulation diversity, we discover that the hierarchical seniority of a TF, as measured 
by the PageRank of a TF in the core TRTG network, is also associated with the (known) function 
diversity (p-value 0.0023, PCC 0.15) and the regulator diversity of a TF (p-value 0.025, PCC 
0.12). There is an even stronger association between PageRank and the target function diversity 
of a TF (p-value 1.2e-42 and PCC 0.62). These indicate that a transcription factor at the top of the 
regulatory hierarchy tends to have more diverse functions. This correlation however may be 
caused by the shared association of PageRank and the target-function diversity with the number 
of target genes of a TF, as they are both defined on the target genes.  Indeed, after controlling for 
the target gene size through a linear model, neither the PageRank-function diversity or PageRank-
target function diversity associations are significant (p-values 0.94 and 0.051 respectively). 
Similar behavior is observed for other TF hierarchical rank measures defined based on breadth 
first search (BFS) and percentage of regulatory target genes (Yu and Gerstein 2006; Bhardwaj et 
al. 2010). 
 
1.7. Gene’s Regulator Diversity and Multifunctionality 
Significant associations between function and regulator diversities of genes are observed for 
specific types of functional annotations (Supplemental Fig. S10), including signaling/metabolic 
pathways (p-value 1.5 × 10-6), biological processes (p-value 1.5 × 10-6), and GWAS phenotypes 
(p-value 1.1 × 10-10), while the diversity of GWAS phenotype of a gene is inversely correlated 
with its regulator diversity. Genes regulated by 10 or more other TFs are 14% less likely to be 
associated with any GWAS phenotypes, and 46% less likely to be associated with 5 or more 
phenotypes. Note that we used the Coding gene universe when analyzing GWAS phenotype 
associations, and the Literature Rich gene universe when analyzing other annotations. Both of 
these are conservative choices of gene universes. Using Literature Rich gene universe will lead to 
more significant negative association between TF regulation and phenotypes, while using Coding 
gene universe will lead to more significant positive associations between TF regulation and 
signaling & metabolic pathways, biological processes, and molecular functions.  
 
We removed the low-throughput data in the TFTG data, and only retained the target genes for 
262 TFs from ChIP-seq studies. The associations of TFs’ regulator diversity with specific types 
of functions are PCC 0.17, p-value 0.007 for GWAS phenotypes; PCC -0.0063, p-value 0.92 for 
Mendelian disease; PCC 0.11 p-value 0.093 for PK & PD pathways; PCC 0.086, p-value 0.17 for 
molecular functions, PCC 0.14, p-value 0.032 for biological processes; PCC 0.15, p-value 0.015 
for signaling & metabolic pathways. Meanwhile, for general genes (TFs and non-TFs), there is 
still a significant positive association between regulator diversity and signaling/metabolic 
pathway diversity (PCC 0.072, p-value 1.3e-6), and a significant negative association for GWAS 
phenotypes (PCC -0.11, p-value 6.8 e-19). 
 
For the 10792 general genes that have regulators, function annotations as well as expression data, 
genes’ regulator diversity and expression diversity are correlated (Spearman rank correlation 0.22, 
p-value 3.7 × 10-120 for diversities, or correlation 0.26, p-value 1.0 × 10-165 for the raw counts), 
and genes’ regulator diversity and function diversity are also correlated (Spearman rank 
correlation 0.12, p-value 1.0 × 10-33). 
 
 2. Supplemental Methods 
2.1. Modified TIP algorithm for Exacting Target Genes from ChIP-Seq Data 
The binding signals from target genes were differentiated from that from non-target genes using a 
modified version of the TIP algorithm (Cheng et al. 2011). Specifically, the modified 
implementation accepts both fixed step and variable step wiggle formatted files as well as other 
commonly used genome feature formats, such as bed and bigWig. It properly handles the 0-based 
start and 1-based end coordinates of transcript annotations and the 1-based coordinates in wig 
files. Genomic regions with read density less than 1 read per million total reads are ignored. In 
addition, it only evaluates the unambiguously mapped transcripts, and removes redundant 
promoter regions (i.e. transcripts with identical TSS are merged). RefSeq gene annotations on 
human genome hg18 and hg19 were obtained from the UCSC genome browser 
(https://genome.ucsc.edu) (Karolchik 2003). Instead of the dot product scoring functions used in 
TIP, we used log likelihood ratio to achieve a Gaussian like distribution of the scores,  
𝑆! = 𝑥!" ∙ log 𝑚!.!"#"𝑚!.!"##!"""!!!!""" , 
where 𝑥!" is the read counts at location 𝑙 within the promoter region, and score 𝑆! for 
promoter/gene 𝑔 is calculated as the read-counts weighted sum of the log likelihood ratio 
between the average signal distribution 𝑚!.!"#" and the even distribution  𝑚!.!"##. A 6k window 
is used spanning ±3K base pairs 5’ and 3’ to the TSS. P-values are then computed by assuming a 
Gaussian distribution of 𝑆!. The target genes of each TF in each experiment are then obtained at 
q-value cutoff of 0.01 (Storey 2003; Storey and Tibshirani 2003). Multiple experiments or data 
sources for the same TF are then merged, resulting in target gene sets for 384 unique transcription 
factors. 
 
 3. Supplemental Figures 
Figure S1:  
A. Transcription factor coverage by three sources of TF-target gene data. LTP: low throughput 
experiments; ENCODE: TF ChIP-seq experiments in ENCODE study; Other ChIP-seq: non-
ENCODE ChIP-seq experiments compiled from GEO. 
B-E. Transcription factor (TF) and target gene (TG) degree distributions in the TFTG data 
compendium and the subset of TF-target TF core network. (B) TG degree (i.e. node in-degree) 
and (C) TF degree (i.e. node out-degree) distributions in the full TFTG data compendium. (D) TG 
degree (i.e. node in-degree) and (E) TF degree (i.e. node out-degree) distributions in the core 
TRTG data compendium for which the TGs are restricted to be only the 384 TFs. 
 
Figure S2:  
Venn diagram showing the overlaps among five types of gene function annotations. Mendelian 
diseases are not included in the Venn diagram due to limitation of the visualization technique. 
 
Figure S3:  
The significance of TF-target function association depends on the choice of gene universe. Shown 
here is the impact of gene universe on the association between TF SP1 and Reactome pathway 
Immune System. Three gene universes are evaluated, while the literature rich gene universe is the 
one used in this study. 
 
Figure S4:  
A. The in-degree and out-degree distributions of the TF-Target Function network follow a power 
law distribution with exponents 1.2 approximately. Left: distribution of the out-degrees of TFs 
(#Functions per TF). Right: distribution of the in-degrees of functions (#TFs per function).  
B. The TFs that are not annotated with any target functions (blue curve) have less target genes 
than TFs that are annotated with one or more target functions. 
 
Figure S5:  
A. Average number of transcription factors shared per pair of function annotations. FDR cutoff 
0.05 was applied to select significant target functions. The clustering is based on 1 – diagonal-
normalized TF sharing, which is 1-average(cosine similarity) of regulator vectors of functional 
concepts. 
B. Shown are heatmap of 62 TFs with significant annotation type biases at q-value cutoff 0.01. 
Clustering are based on cosine similarity of the counts of significant TF-Target function 
associations. The color in the heatmap correspond to log(Cij*C++/Ci+*C+j), where Cij is the 
counts for TF i and function type j, C++ is the total count, Ci+ is the total number of significant 
target functions for TF i, and C+j is the total number of significant TFs for a function type j. 
Positive values (red) indicate favored function types, and negative values (all set to -1, green 
color) indicate disfavored function types.  
 
 
Figure S6:  
Receiver Operator Characteristics (ROC) curves measuring the predictive performances of TF-
Target function associations (phi) against known TF-function annotations. AUC, area under the 
ROC curve; FET, Fisher’s Exact Test; Centered p-value, 2 times the min of the two single tailed 
FET p-values. 
 
Figure S7:  
Clustering of TFs by target gene-based TF-TF similarity (measured by Pearson’s phi). In the 
heatmap, colors green to red correspond to negative to positive TF-TF target gene associations. 
Hierarchical clustering of TFs is performed using 1-phi as distance measure. Six selected sub-




Evolutionary and functional trees of 384 TFs covered by the TFTG data compendium.  
(A) Protein sequence based phylogenetic trees of TFs. Sequence similarity based clustering of 
transcription factors using UPGMA.  
(B) Target-gene similarity (phi) based functional clustering of transcription factors, same as the 




Functional concepts that share TFs do not necessarily share member genes significantly.  
(A) Two target functional concepts with 100% member gene overlaps always have identical 
regulators, but (B) two functional concepts with 100% identical regulators do not always have 
high member gene sharing.  
 
Figure S10: 
Significant association exists between the regulator diversity and functional diversity of 11345 
genes that have both regulators and function annotations.  
(A) Six types of function annotations are analyzed separately and significant positive association 
is observed for biological processes and signaling/metabolic pathways.  
(B) Estimated odds ratio for tightly regulated genes (number of TF >= 10) versus annotated genes 
(number of annotation > 0). 
 
Figure S11: 
The upstream regulators and downstream (target) functions of TFs (A) NFKB1 and (B) RFX5, 
and non-TF gene MTHFR. The coloring schema is same as in Figure 5 and the clustering of TFs 
and functions are based on the target gene and member gene overlaps. 
 
Figure S12:  
Transcription factor’s regulator diversity is associated with target function diversity. Pearson 
correlation is 0.32, p-value 3.3e-10; and for the TF with over 100 target genes, correlation is 0.35, 
p-value 6.0e-06. HNF1A is highlighted in red. 
  


























































































































































































































































Positive association:  
p-value = 3.2$×$10(5; odds ratio = 
1.9; FDR = 2.8$×$10(3$ 
SP1 Immune System
Coding Genes All Reactome Genes
Negative association: 
p-value = 0.41; odds ratio = 0.97 






p-value = 0.086; odds ratio = 1.2 

























































































































































0.16 0.08 0.03 0.14 0.08 0.17
0.08 0.22 0.04 0.09 0.03 0.12
0.03 0.04 0.29 0.27 0.18 0.18
0.14 0.09 0.27 1.29 0.75 0.86
0.08 0.03 0.18 0.75 0.6 0.59
































































































































   GWAS phenotype
association φ2, AUC =0.712
association φ, AUC =0.45


































































   Mendelian disease
association φ2, AUC =0.789
association φ, AUC =0.603


































































   PK & PD pathways
association φ2, AUC =0.847
association φ, AUC =0.85
Centered FET p−value, AUC 0.854








































   molecular functions
association φ2, AUC =0.702
association φ, AUC =0.663

































































   biological processes
association φ2, AUC =0.745
association φ, AUC =0.652

































































   signaling/metabolic pathways
association φ2, AUC =0.759
association φ, AUC =0.717



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. Supplemental Tables 
 
Table S1: A summary of the total number and effective number of concepts in each of the 
6 function annotation databases. Phenotype: complex phenotypes studied in GWAS; 
Diseases: Mendelian Diseases; PharmGKB: PK & PD pathways from PharmGKB; MF: 
Molecular Functions from GO; BP: Biological processes from GO; Pathways: Signaling & 
Metabolic Pathways from Reactome. 
 
Phenotype Disease PharmGKB MF BP Reactome 
Functional Concept 
Counts 573 1156 91 396 825 674 
Within DB 
Redundancy-
Adjusted Counts 467.7 551 44.9 176.8 225.2 217.3 
Between DB 
Redundancy-
Adjusted Counts 368.4 465.3 24.8 115.3 178.7 163.3 
 
Table S2. Average number of significant functional concept enrichments per transcription factors 
at FDR 0.05. Coding gene universe is used for phenotypes and literature rich gene universe for 
the rest. 
 
Phenotype Disease PharmGKB MF BP Reactome 



















































































































































































Table S3: TFs and their target complex phenotypes at FDR 0.05. The Coding gene universe is 
used for the association analysis. Only enrichment (positive associations) and the corresponding 
single tailed p-values are shown. log2(OR): log2 transformed odds ratio. Evidence: lists published 
genetic evidence directly supports the association of the TF with the disease; Mutation: mutations 
of the TF are observed in the disease or closely related diseases. Association: The TF gene locus 
is genetically associated with the disease or related diseases. Mouse: mouse model shows 
phenotypes directly related to the disease. Non-genetic evidence in the literature is not considered. 
# MHC II: RFX5 is mutated in Bare lymphocyte syndrome II (DeSandro et al. 1999; Reith and 
Mach 2001), and RFX5 knock out mouse shows abnormality in the immune system (Masternak et 
al. 1998; Clausen et al. 1998) 
TF Phenotype log2(OR) P-value Evidence 
AHR Coffee consumption 12.5 2.3E-07 Association (Sulem et al. 2011; 
Cornelis et al. 2011, 2015) 
Habitual caffeine 
consumption 
10.1 5.0E-06 Association (Sulem et al. 2011; 
Cornelis et al. 2011, 2015) 
HNF1A Serum cell-free DNA 
(Cardiovascular 
Risk) 
8.9 1.3E-09 Association (Reiner et al. 2009), 












Mouse (Pontoglio et al. 1996) 
NFKB1 Psoriasis 3.6 1.1E-07 - 
Ulcerative colitis  3.3 5.1E-07 Association (Jostins et al. 2012) 
Rheumatoid arthritis     3.2 4.0E-09 - 
POU2F2 Celiac disease 4.2 4.7E-06 - 
RFX5 Chronic hepatitis b 7.1 8.2E-06 - 
Nasopharyngeal 
neoplasms 
6.5 9.5E-07 - 
Systemic 
scleroderma  
6.1 2.8E-10 MHC II # 
Leprosy 4.7 7.5E-10 - 
Psoriasis 3.7 4.9E-06 MHC II # 
Type 1 diabetes 
mellitus 
3.7 1.9E-09 MHC II # 
Multiple sclerosis 3.3 2.4E-08 MHC II # 
Behcet syndrome 3.3 8.8E-06 MHC II # 
Systemic lupus 
erythematosus 
3.2 1.0E-06 MHC II # 
SREBF1 Low density 
lipoproteins (LDL) 
3.9 2.2E-06 Mouse (Shimano et al. 1997) 
TBP Systemic 
scleroderma  
4.8 5.9E-06 - 
 
 
Table S4: TF and their target pharmacogenomic pathways at FDR 0.05. The Literature Rich gene 
universe is used for the association detection. Log2(OR), log2 transformed odds ratio; P-value: p-
value from single-tailed Fisher’s exact test for odds ratio > 1; Evidence: For the PD pathways, we 
listed direct evidence supporting the TF-PD pathway relationship if, 1) Member: the TF is 
annotated as a member gene in same or closely related PharmGKB/Reactome pathways or GO 
biological processes; 2) Census or Mutation: the TF is a known causal gene of the diseases based 
on Cancer Gene Census (Futreal et al. 2004) or OMIM (Hamosh et al. 2005); 3) GWAS: the TF 
gene locus is strongly associated with related phenotypes in GWAS. 4) Mouse: mouse model 
shows phenotypes directly related to the disease. Other forms of evidence in the literature are not 
considered. * PD pathways containing 50% or more PK genes. & neural normal: this is not disease 





value Diseases Evidence 
AHR Amodiaquine Pathway (PK) 11.6  8.4E-07 N/A N/A 
 Warfarin Pathway (PK) 9.8  7.9E-06 N/A N/A 
 Estrogen Metabolism 
Pathway 
9.6  4.9E-08 N/A N/A 
 Erlotinib Pathway (PK) 9.6  1.0E-05 N/A N/A 
 Phenytoin Pathway (PK) 8.3  5.3E-05 N/A N/A 
ATF1 Busulfan Pathway (PD) 4.0  6.9E-05 Cancer Mutation: melanoma 
(Futreal et al. 2004) 
ATF2 ACE Inhibitor Pathway (PD) 6.3  3.0E-05 
Hypertension -  Agents Acting on the Renin-
Angiotensin System Pathway 
(PD) 
6.3  3.0E-05 
BRF1 Imatinib Pathway (PK & PD) 8.0  8.0E-05 Cancer - 
BRF2 Imatinib Pathway (PK & PD) 7.7  1.2E-04 Cancer - 
CREB1 Sympathetic Nerve Pathway 
(Neuroeffector Junction) 





E2F1 Antimetabolite Pathway - 
Folate Cycle (PD) 
 









Member: multiple GO 
terms for Cell cycle control 
 
Member: multiple GO 
terms for Cell cycle control 
 
Member: multiple GO 
terms for Cell cycle control 
 Thiopurine Pathway (PK & 
PD) 
 
3.1  3.2E-05 
 Methotrexate Pathway 
(Cancer Cell) (PD) 
3.1  1.3E-04 
E2F4 Antimetabolite Pathway - 
Folate Cycle (PD) 
3.5  2.7E-05 Cancer & 
autoimmune 
diseases 
Member: multiple GO 
terms for Cell cycle control 
EGR1 EGFR Inhibitor Pathway 
(PD) 
2.6  4.5E-05 Cancer - 
ELK1 EGFR Inhibitor Pathway 
(PD) 
5.6  5.8E-06 Cancer Member: PharmGKB 
(EGFR Inhibitor Pathway) 
ETS1 Vinka Alkaloid Pathway 
(PK) 
4.9  6.2E-05 N/A N/A 
 Doxorubicin Pathway 
(Cancer Cell) (PD) 
4.1  5.2E-05 Cancer Member: PharmGKB 
(EGFR Inhibitor Pathway) 
Member: PharmGKB 
(EGFR Inhibitor Pathway) 
 Vemurafenib Pathway (PD) 3.9  2.2E-05 Cancer 
(melanoma) 
 Platelet Aggregation 
Inhibitor Pathway (PD) 
3.2  2.0E-05 thrombosis - 
ETV4 ACE Inhibitor Pathway (PD) 5.6  1.1E-04 hypertension 
 
- 
 Agents Acting on the Renin-
Angiotensin System Pathway 
(PD) 
5.6  1.1E-04  
 Celecoxib Pathway (PD) 4.6  8.2E-06 pain - 
FOS Platinum Pathway (PK & 
PD) 
4.4  3.2E-05 Cancer 
 
Member: PharmGKB 
(EGFR Inhibitor Pathway) 
 Doxorubicin Pathway 
(Cancer Cell) (PD) 
4.1  1.3E-05 Cancer Member: PharmGKB 
(EGFR Inhibitor Pathway) 
FOXA1 Benzodiazepine Pathway 
(PK) 
4.6  1.1E-04 N/A N/A 
FOXA2 Carbamazepine Pathway 
(PK) 
4.4  2.1E-05 N/A N/A 
 Phenytoin Pathway (PK) 4.0  7.0E-05 N/A N/A 
HIF1A Glucocorticoid Pathway 
(Peripheral Tissue) (PD) 
6.0  6.3E-05 Inflammation Member: GO cytokine 
production 
HNF1A Artemisinin and Derivatives 
Pathway (PK) 
8.4  5.4E-07 N/A N/A 
 Tramadol (PK) 8.1  9.4E-07 N/A N/A 
 Losartan Pathway (PK) 8.0  9.2E-05 N/A N/A 
 Sorafenib(PK) 7.6  1.4E-04 N/A N/A 
 Mycophenolic acid Pathway 
(PK) 
7.4  1.2E-09 N/A N/A 
 Irinotecan Pathway (PD*) 7.3  7.4E-08 Cancer Mutation: renal cell 
carcinoma (Rebouissou et 
al. 2005)  
 Benzodiazepine Pathway 
(PK) 
7.3  4.4E-06 N/A N/A 
 Valproic Acid Pathway (PK) 7.0  4.0E-09 N/A N/A 
 Irinotecan Pathway (PK) 7.0  7.6E-06 N/A N/A 
 Tamoxifen Pathway (PK) 6.9  2.3E-07 N/A N/A 
 Estrogen Metabolism 
Pathway 
6.7  1.2E-05 N/A N/A 
 Phenytoin Pathway (PK) 6.3  3.0E-05 N/A N/A 
 Statin Pathway (PD) 5.9  5.9E-05 High 
cholesterol  
Association (Teslovich et 
al. 2010) 
 Anti-diabetic Drug Potassium 
Channel Inhibitors Pathway 
(PD) 
5.7  8.4E-05 Diabetes Mutation: diabetes, type 1 
(Yamada et al. 1997) and 
type 2 (Hegele et al. 1999)  
HNF1B Methotrexate Pathway (PK) 9.3  1.5E-05 N/A N/A 
HNF4G Statin Pathway (PD) 4.7  6.5E-05 High 
cholesterol  
Weak Association 
(Kathiresan et al. 2007) 
HOXA5 Doxorubicin Pathway 
(Cancer Cell) (PD) 
8.2  6.0E-05 Cancer Mouse: abnormal cell 
migration (Mandeville et al. 
2006) 
HSF1 Glucocorticoid Pathway 
(Peripheral Tissue) (PD) 
7.1  6.4E-06 Inflammation Mouse (Xiao et al. 1999) 
KLF11 Anti-diabetic Drug Potassium 
Channel Inhibitors Pathway 
(PD) 
9.2  2.1E-05 Diabetes Mutation (Neve et al. 2005) 
MYC Antimetabolite Pathway - 
Folate Cycle (PD) 
3.9  4.5E-06 Cancer & 
autoimmune 
diseases 
Member: GO cell cycle 
control;  
Census (Collins and 
Groudine 1982; Yokota et 
al. 1986);  
 Thiopurine Pathway (PK & 
PD) 
2.4  8.6E-05 Cancer & 
autoimmune 
diseases 
Member: GO cell cycle 
control;  
Census (Collins and 
Groudine 1982; Yokota et 
al. 1986); 
NFKB1 Doxorubicin Pathway 
(Cancer Cell) (PD) 
4.4  3.8E-06 Cancer 
 
Cancer 
- (Strong literature evidence 
but no mutation) 
-  EGFR Inhibitor Pathway 
(PD) 
3.1  8.9E-07 
NR1I2 Clopidogrel Pathway (PK) 6.1  4.7E-05 N/A N/A 
NR1I3 Fluvastatin Pathway (PK) 11.3  1.5E-06 N/A N/A 
 Atorvastatin/Lovastatin/Simv
astatin Pathway (PK) 
11.2  1.7E-06 N/A N/A 
 Statin Pathway - 
Generalized(PK) 
10.7  3.6E-06 N/A N/A 
 Phenytoin Pathway (PK) 10.7  3.6E-06 N/A N/A 
NR2C2 Imatinib Pathway (PK & PD) 7.7  1.2E-04 Cancer - 
PDX1 Anti-diabetic Drug Potassium 
Channel Inhibitors Pathway 
(PD) 
9.2  2.1E-05 Diabetes Mutation (Macfarlane et al. 
1999; Hani et al. 1999) 
PHOX2
A 
Sympathetic Nerve Pathway 
(Neuroeffector Junction) 
9.9  9.9E-06 Neural 
normal& 
Mouse (Coppola et al. 
2010) 
PPARA Statin Pathway (PD) 6.3  3.8E-08 High 
cholesterol  
Mutation (Vohl et al. 2000) 
 Celecoxib Pathway (PD) 4.6  7.8E-05 Pain - 
PPARD Statin Pathway (PD) 6.4  2.1E-05 High 
cholesterol  
Mouse (Gross et al. 2011) 
RARA Aromatase Inhibitor Pathway 
(Breast Cell) (PD) 





Census  EGFR Inhibitor Pathway 
(PD) 
4.0  1.1E-05 
RARB Vemurafenib Pathway (PD) 5.6  1.0E-04 Cancer 
Cancer 
- 
-  EGFR Inhibitor Pathway 
(PD) 
4.5  1.0E-04 
RDBP Imatinib Pathway (PK & PD) 8.0  8.0E-05 Cancer - (Involved in cancer, not 
through genetic mutation) 
REST Sympathetic Nerve Pathway 
(Pre- and Post- Ganglionic 
Junction) 
4.9  6.9E-05 Neural 
normal& 
Mouse: thick retinal 
ganglion layer (Mao et al. 
2011) 
RXRA Statin Pathway (PD) 5.4  6.1E-08 High 
cholesterol  
- 
SP1 Vinka Alkaloid Pathway 
(PK) 
4.6  5.2E-06 N/A N/A 
 Erlotinib Pathway (PK) 4.3  5.7E-05 N/A N/A 
 Etoposide Pathway (PK & 
PD) 
3.9  7.3E-06 Cancer - 
 Statin Pathway (PD) 3.8  3.4E-08 High 
cholesterol  
- 
 EGFR Inhibitor Pathway 
(PD) 
2.1  7.3E-05 Cancer - 
SREBF1 Bisphosphonate Pathway 
(PD) 
5.7  3.0E-07 Osteoporosis - 
 Statin Pathway (PD) 5.3  7.0E-08 High 
cholesterol  
Mouse Knockout (Liang et 
al. 2002) 
SREBF2 Bisphosphonate Pathway 
(PD) 
6.8  9.3E-09 Osteoporosis - 
 Statin Pathway (PD) 6.4  1.1E-09 High 
cholesterol  
Mouse Knockout (Liang et 
al. 2002) 
STAT1 EGFR Inhibitor Pathway 
(PD) 
3.1  1.9E-05 Cancer - 
STAT5A Aromatase Inhibitor Pathway 
(Breast Cell) (PD) 
8.9  2.8E-05 Breast & 
ovarian cancer 
- 
STAT5B Aromatase Inhibitor Pathway 
(Breast Cell) (PD) 
8.9  2.6E-05 Breast & 
ovarian cancer 
Cancer Gene Census 
TFAP2A Sympathetic Nerve Pathway 
(Neuroeffector Junction) 





facial syndrome (Lin et al. 
2000; Milunsky et al. 2008; 
Gestri et al. 2009) 
  Celecoxib Pathway (PD) 3.2  4.3E-07 Pain 
 EGFR Inhibitor Pathway 
(PD) 
2.6  8.8E-05 Cancer  
- 
TP53 Doxorubicin Pathway 
(Cancer Cell) (PD) 
5.2  2.0E-09 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990) 
 Vinka Alkaloid Pathway 
(PK) 
5.0  4.6E-05 - - 
 Etoposide Pathway (PK & 
PD) 
4.6  1.3E-05 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
 Busulfan Pathway (PD) 4.2  3.9E-09 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
 Vemurafenib Pathway (PD) 4.0  1.5E-05 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
 Methotrexate Pathway 
(Cancer Cell) (PD) 
4.0  2.6E-06 Cancer & 
autoimmune 
diseases 
Census (Chen et al. 1990; 
Halevy et al. 1990); Normal 
immune response (Chiang 
et al. 2012) 
 Doxorubicin Pathway (PK) 3.9  1.0E-04 - - 
 EGFR Inhibitor Pathway 
(PD) 
3.4  2.4E-08 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
USF1 Theophylline Pathway (PK) 6.0  1.2E-04 - - 
WT1 Doxorubicin Pathway 
(Cancer Cell) (PD) 
6.6  4.6E-07 Cancer Census (Pelletier et al. 
1991) 
 Doxorubicin Pathway (PK) 5.8  6.7E-05 - - 
 Vemurafenib Pathway (PD) 5.6  1.0E-04 Cancer Census (Pelletier et al. 
1991) 
YBX1 Erlotinib Pathway (PK) 9.9  6.7E-06 - - 
 
 
Table S5. The tables list the functional concepts with the highest and lowest unique 
scores from 6 sources of gene function annotations. The uniqueness score are computed 
with all data sources merged. 
GWAS Phenotypes Uniqueness Mendelian Diseases Uniqueness 
oligospermia 1 anauxetic dysplasia 1 
cd8-positive t-lymphocytes 1 polycystic ovary syndrome 1 
t-lymphocytes 1 intracranial arterial disease 1 
serotonin 1 Moyamoya disease 1 
transforming growth factor 
beta1 
1 Mobius syndrome 1 
lymphoma, follicular 0.24 papilloma 0.1 
hepatitis b, chronic 0.24 choroid plexus papilloma 0.1 
myeloproliferative disorders 0.23 adrenocortical carcinoma 0.1 
alopecia 0.22 adrenal gland cancer 0.1 




Uniqueness GO MF Uniqueness 
PA165947317_Leukotriene_
modifiers_pathway_PD 


















































































































Table S7: The complete TF annotation results. -Log10 (p-value) are provided in 
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